Stock BCAB BIOATLA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News BioAtla, Inc.

Equities

BCAB

US09077B1044

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
1.51 USD -0.33% Intraday chart for BioAtla, Inc. -11.70% -38.62%
May. 23 BioAtla, Inc. Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology Annual Meeting CI
May. 15 Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Ahead of Key Inflation, Retail Data MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BioAtla to Participate in the Jefferies Global Healthcare Conference
AQ
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
BioAtla, Inc. Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology Annual Meeting
CI
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Ahead of Key Inflation, Retail Data
MT
BioAtla Shares Jump 10% in Premarket Activity Wednesday as Diluted Net Loss Narrows in Q1
MT
Transcript : BioAtla, Inc., Q1 2024 Earnings Call, May 14, 2024
BioAtla : BCAB_Corp_Update_May 2024_FINALv3
PU
BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress
AQ
BioAtla, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
BioAtla to Participate in the Citizens JMP Life Sciences Conference
AQ
BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024
AQ
BioAtla's Multiple Cancer Drug Candidate Receives FDA Clearance
MT
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors
AQ
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors
CI
BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
HC Wainwright Adjusts BioAtla's Price Target to $7 From $10, Maintains Buy Rating
MT
Transcript : BioAtla, Inc., Q4 2023 Earnings Call, Mar 26, 2024
BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
AQ
BioAtla, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BCAB Stock
  4. News BioAtla, Inc.